Log In
BCIQ
Print this Print this
 

PRS-343

  Manage Alerts
Collapse Summary General Information
Company Pieris Pharmaceuticals Inc.
DescriptionAnticalin targeting tumor necrosis factor (TNF) receptor superfamily member 9 (4-1BB; TNFRSF9; CD137) combined with a HER2-targeting mAb
Molecular Target Tumor necrosis factor (TNF) receptor superfamily member 9 (4-1BB) (TNFRSF9) (CD137) ; Epidermal growth factor receptor 2 (HER2) (EGFR2) (ErbB2) (neu)
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPreclinical
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today